An Observational, Multicenter, National Study with Real-life Retrospective Data Collection on the Combined Use of Sibutramine and Topiramate As Anti-obesity Treatment in Overweight Patients with Comorbidity(ies) or Obesity.

Eurofarma Laboratorios S.A.2 sites in 1 country1,500 target enrollmentDecember 1, 2024

ConditionsOverweight Obesity

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Overweight
Sponsor: Eurofarma Laboratorios S.A.
Enrollment: 1500
Locations: 2
Primary Endpoint: The percentage of patients who achieved a weight loss greater than 5%
Status: Withdrawn
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

An observational, multicenter, national study with retrospective real-life data collection on the combined treatment of sibutramine and topiramate (off-label use) for the treatment of overweight with comorbidity(ies) or obesity. Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be included in the study.

Registry

clinicaltrials.gov

Start Date

December 1, 2024

End Date

December 1, 2025

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Eurofarma Laboratorios S.A.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Adult patients
•Both sexes
•Diagnose of overweight with comorbidity(ies) or obesity
•Treatment use of sibutramine combined with topiramate
•Treatment prescription between 2011 and the beginning of the study

Exclusion Criteria

•Use of topiramate for other condition besides overweight with comorbidity(ies) or obesity
•Individual use of one of the medications (sibutramine or topiramate)